A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration

Trial Profile

A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Pegpleranib (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 31 Oct 2016 Primary endpoint has been met. (Mean change in visual acuity from baseline at the Week 24 visit), as per OphthoTech Corporation media release.
    • 31 Oct 2016 Results published in the journal of the American Academy of Ophthalmology, as per OphthoTech Corporation media release.
    • 31 Oct 2016 Results from this trial published online in Ophthalmology, the journal of the American Academy of Ophthalmology, as per OphthoTech Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top